A trial fibrillation is the most common sustained disturbance of cardiac rhythm. It is a global epidemic and an evolving problem in cardiovascular medicine. Atrial fibrillation is an independent risk factor for embolic stroke, increasing the risk of stroke five-fold. Despite good evidence for the reduction of stroke risk with anticoagulant therapy, there is significant under treatment. Anticoagulant prescribing is frequently discordant with all current guidelines and decision aids with both over and under use of oral anticoagulants. It is important that GPs have up-to-date knowledge about atrial fibrillation in terms of both its diagnosis and management, and that patients have an understanding of anticoagulant medication. This article aims to update knowledge about atrial fibrillation, the use and benefits of anticoagulation with insights on some barriers to anticoagulation in primary care. This article does not cover management of atrial fibrillation with control of cardiac rate or rhythm to maintain cardiac function.
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The GP curriculum and atrial fibrillation Clinical module 3.12: Cardiovascular health states that atrial fibrillation is commonly seen in general practice and GPs should be able to: . Make an initial diagnosis by eliciting appropriate signs and symptoms . Investigate and manage atrial fibrillation . Describe strategies for early detection of atrial fibrillation in both symptomatic and asymptomatic patients . Demonstrate an understanding of risk factors, including chronic kidney disease in the diagnosis and management of cardiovascular problems
. Consider whether co-morbidities are present and manage these appropriately
. Describe key research findings influencing the management of cardiovascular problems
. Appreciate the importance of the social and psychological impact of cardiovascular problems on the patient, their family, friends, dependants and employers
. Co-ordinate and commission care with other primary care health professionals, cardiologists and other appropriate specialists, leading to effective and appropriate acute and chronic disease management; including prevention, rehabilitation and palliative care for those with end stage cardiac failure
Atrial fibrillation: Why is this important?
Atrial fibrillation (AF) is projected to develop in a quarter of the cohort of 40-year-old adults (Schnabel et al., 2015; WHO, 2014) . AF is an independent risk factor for stroke and myocardial infarction, and can lead to sudden death or heart failure (HF) even in well anticoagulated patients (Andersson et al., 2013; Chugh et al., 2018) . The prevalence of AF and the associated morbidity increase with age. Data obtained in the seminal Framingham study revealed that approximately 1% of patients with AF are less than 60 years of age. Up to 12% of patients with AF are aged between 75 and 84 years (Wolf et al., 1996) , and more than one third of patients with AF are over 80 years of age (Camm et al., 2010) . The prevalence of AF is expected to increase considerably with an ageing population. Ziff et al. (2018) assessed the all-cause mortality and length of hospital stay in patients with chronic and new-onset concomitant AF and HF in an analysis report on 929 552 adult patients admitted to seven hospitals in the North of England. The authors demonstrated that the co-existence of AF with HF conferred higher mortality and longer hospital stay compared with patients without the combination (Ziff et al., 2018) .
Additionally, patients with resolved AF remain at higher risk of stroke compared with patients without AF (Staerk et al., 2018) . Recently, data from practices contributing to 'The Health Improvement Network' demonstrated an increased risk of stroke in patients without documented recurrent AF (Adderley et al., 2018) . Taken together, these findings have obvious implications for public health policy and health costs (Deshpande et al., 2018) .
Pathophysiology of atrial fibrillation
AF is characterised by disorganised atrial electrical activity and contraction, which leads to impaired atrial contribution to cardiac output. In primary care, AF can present with a wide range of forms and symptoms from asymptomatic to severe, with frequent hospitalisations, significant morbidity and mortality (January et al., 2014) . Most patients will present with fatigue (commonest), palpitations, shortness of breath, hypotension, fainting episodes, and symptoms of HF. It is important to note that most people with AF will not have a stroke; however, neurological symptoms of a new stroke can be the presenting symptoms for some patients.
Diagnosis of atrial fibrillation
Diagnosis of AF starts with a focussed clinical history, including presenting symptoms, duration of symptoms, characteristic pattern (Table 1) , prior treatment, family history, associated conditions (renal, atherosclerosis, peripheral vascular disease, inflammatory bowel disease, malignancy), and potentially reversible risk factors (heart disease, inflammatory disease, thyroid disease, alcohol, obesity, drugs, infections).
If examination then reveals an irregular pulse, all patients with suspected AF need confirmation from an electrocardiogram (ECG). A 12-lead ECG of AF shows an irregular R-R interval, absence of distinct P-waves and irregular atrial activity (Fig. 1) . Ambulatory electrocardiography may be needed to confirm the diagnosis of intermittent AF. Blood tests can help exclude reversible risk factors and should include full blood count, thyroid function tests, urea and electrolytes, calcium, magnesium, liver function tests and clotting profile. A chest radiograph is required if pulmonary disease or HF is suspected and can, for example, identify cardiomegaly, pleural effusion or pneumonia.
Echocardiography does not need to be performed in every patient with AF. It is necessary to exclude associated valvular heart disease or myocardial abnormalities (for example, with detection on examination of heart murmers or heart failure), as a baseline for longer-term management or to further assess risk. In secondary care, this may be with transthoracic echocardiography. Further diagnostic tools for AF, usually in secondary and specialist cardiac centres, include ambulatory rhythm monitoring (e.g. telemetry, Holter monitor, and event Long standing persistent AF . Continuous for a duration of more than 12 months Permanent AF . Following a joint decision by the patient and clinician to cease further attempts to restore and/or maintain sinus rhythm . Acceptance of AF represents a therapeutic attitude on the part of the patient and clinician rather than an inherent pathophysiological attribute of the AF . Acceptance of AF may change as symptoms, the efficiency of therapeutic interventions, and patents and clinician preferences evolve Non-valvular AF . Absence of rheumatic mitral stenosis, a mechanical or bio prosthetic heart valve, or mitral valve repair recorders) implanted loop recorders, and in rare cases, electrophysiological studies (January et al., 2014) .
Updated management steps for anticoagulation in atrial fibrillation
The latest National Institute for Health and Care Excellence (NICE) guideline recommendation is to offer people with AF a personalised package of care and ensure that it covers stroke awareness and measures to prevent stroke, rate control, assessment of symptoms for rhythm control, and who to contact for advice and psychological support if needed (NICE, 2014) . Further recommendations include the use of CHA 2 DS 2 -VASc stroke risk score (Table 2) to assess stroke risk in people with symptomatic or asymptomatic paroxysmal, persistent or permanent AF, atrial flutter or patients with continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm (NICE, 2014) .
The risk of bleeding in anticoagulated patients is well known. It is currently recommended to assess bleeding risk with the HAS-BLED score (Table 3) and to offer modification and monitoring of associated risk factors, including poorly controlled hypertension, poor control of international normalised ratio (INR), concurrent medication (particularly non-steroidal antiinflammatory drugs, or antiplatelet agents) and harmful alcohol consumption (NICE, 2014) . Although the HAS-BLED bleeding risk score is widely accepted and has been validated in several clinical scenarios (NICE, 2014) , it shares common components to those of the CHA 2 DS 2 -VASc stroke risk score and may lead to patients being inappropriately denied anticoagulation. The recent European Society of Cardiology (ESC) guideline does not recommend any clinical score to assess bleeding risk in AF patients and focuses on modifiable clinical factors Kotecha et al., 2018) .
Most AF patients can be managed in primary care. However, there is a role for a multidisciplinary team approach consisting of GPs, cardiologists, cardiac electrophysiologists, pharmacists, nurse specialists, echocardiographers, advanced cardiac imaging specialists and healthcare policy makers . A stepwise and integrated approach Barriers to effective use of anticoagulants AF is very often asymptomatic and picked up on opportunistic testing. The asymptomatic nature of AF in some patients may make them reluctant to accept treatment, and GPs may need to negotiate and come to agreement with them on the value of effective anticoagulation to prevent stroke. Some GPs express concerns about anticoagulation and are reluctant to prescribe anticoagulants, often for legitimate reasons (Box 2) (Steffel et al., 2018; Ziff et al., 2018) . The choice of an anticoagulant between Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs) can pose a significant challenge in primary care (Karlsson et al., 2018; Pugh et al., 2011) .
VKA (warfarin) versus DOACs: Pros and cons
VKAs are a cheaper alternative to DOACs, more easily reversible and with more widely understood side effects, interactions and complications among patients and doctors. They are therefore perceived as tested and trusted anticoagulants. It is important also to consider that DOACs are not an option if the AF is due to valvular heart disease. However, drug interactions, allergies, contraindications or inability to comply with monitoring constitute a significant problem in 11% of patients. About 41.7% of patients on a VKA fail to achieve 5 65% time within therapeutic range (TTR). Although cost is a perceived barrier to the use of DOACs, NICE (2014) has concluded that the drugs are cost-effective and that all four DOACs (Apixaban, Dabigatran, Edoxaban and Rivaroxaban) must be available to patients within their licensed indications. Coyle et al. (2013) evaluated the costeffectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with AF (Coyle et al., 2013) . Ying Zheng et al. (2014) in a comparison of the cost-effectiveness found Dabigatran preferable to Rivaroxaban and Apixaban. The cost of Apixaban and further evidence on the impact of major and minor bleeds with Dabigatran may influence the choice of DOAC (Coyle et al., 2013) . DOACs come off patent very soon, and are expected to be much cheaper over the next few years.
Good adherence is even more important with the DOACs than with VKAs due to the drugs' relatively short half-lives. With warfarin, patients retain some benefit for 48-72 hours after missing a dose whereas with DOACs, the anticoagulant effect fades rapidly after 12-24 hours. Invariably, the relative shorter half-life of DOACs is an advantage when the need to reverse anticoagulation arises (NICE, 2014) .
For patients, key factors in favour of DOACs include quality-of-life benefits from removing the lifestyle restrictions and monitoring requirements associated with warfarin. Nevertheless, some patients are reassured by regular INR monitoring and so may prefer warfarin. Some patients are concerned about the lack of a specific reversal agent with DOACs, and some patients choose to have no anticoagulant therapy.
In favour of DOACs is their rapid and reliable onset of action, a short half-life and a low potential for food and drug interactions (except that Rivaroxaban must be taken with food). Use of DOACs does not require frequent, routine monitoring, and is therefore, less restrictive on lifestyle (NICE, 2014). However, DOACs are difficult to titrate and require dose adjustment in renal failure. They also lack available reversal strategies and antidotes.
The recent ESC guideline suggests that in non-valvular AF, if eligible for use, a DOAC should be used in preference to a VKA . DOACs are becoming more popular and are increasingly prescribed in preference to VKAs.
Renal function monitoring with DOACs is important. The creatinine clearance (CrCl) is monitored using the Cockcroft Gault formula not the estimated Glomerular Filtration Rate (eGFR). If the CrCL is above 60 ml/min recheck renal function (Cate et al., 2017) . With respect to reversibility, activated charcoal can be used to reduce absorption (unless contraindicated), in overdose or accidental ingestion of DOACs and is recommended for use within 2 hours. Dabigatran is a direct thrombin inhibitor and is dialyzable, due to low plasma binding levels; levels can be decreased by at least 50% after a 4-hour session. However, Edoxaban, Rivaroxaban and Apixaban are direct factor Xa inhibitors and are not expected to be dialyzable. There are new and available DOAC reversal agents such as Prothrombin Complex Concentrates (PCC), Three-factor PCC (PCC3), Four-factor PCC (PCC4) for Rivaroxaban, activated PCC and Recombinant Factor VIIa. This is an area of ongoing development and there remains some degree of uncertainty in the use of DOAC reversal agents (Awad and Cocchio, 2013; Cate et al., 2017; Shaw and Siegal, 2018) .
Antidotes in development include Idarucizumab: a humanised antibody fragment that binds Dabigatran with high affinity to prevent dabigatran inhibition of thrombin. It has a dose-dependent reversal and is well tolerated. Both the US Food and Drug Administration and the European Medicines Agency following the phase III trial now approve Idarucizumab. Another possible antidote for DOACs that is still in development is Andexanet alfa Factor Xa decoy, which targets and sequesters direct and indirect Factor Xa inhibitors (Cate et al., 2017; Pollack et al., 2015; Shaw and Siegal, 2018) . Although the above reversal strategies are not yet available in primary care, they can be used off-licence by specialists in secondary and tertiary centres.
A general practice management plan for prevention of thromboembolism
The prevalence of AF is high in athletes who perform in endurance events and members of the general population with obesity, sleep apnoea, chronic kidney disease (CKD) and with a high alcohol intake. Management of AF starts with consideration of any modifiable risk factors for AF, such as obesity, especially if associated with sleep apnoea. Box 3 considers these and other modifiable risk factors. The role of interventions such as long-term directed weight management was recently reported by Middeldrop et al. (2018) . The study of 355 overweight or obese participants with AF demonstrated that a weight loss of 5 10% reduced AF from persistent to paroxysmal or stopped AF in 88% of participants achieving the targeted weight loss (Middeldorp et al., 2018) .
The adoption of risk-based antithrombotic management of AF based on individualised, shared decision-making can increase uptake of anticoagulation therapy for both symptomatic and asymptomatic AF patients.
Shared decision-making should first consider the absolute and relative risks of stroke and bleeding, taking account of the patient's values and preferences. It is vital that patients have a full risk assessment. The selection of antithrombotic medication should be based on risk assessment, irrespective of the pattern of AF (paroxysmal, persistent, longstanding or permanent). The NICE guideline (NICE, 2014) recommends a Box 4. Summary of recommended management tips for non-valvular atrial fibrillation.
. CHA 2 DA 2 -VASc score of 0 to omit antithrombotic therapy . CHA 2 DA 2 -VASc score of 52 with end stage CKD *creatinine clearance <15 mL/min, it is reasonable to administer warfarin (INR 2.0 -3.0)
. For patients with AF and a mechanical valve undergoing procedures that require interruption of warfarin, a bridging therapy with unfractionated or low-molecular-weight heparin is recommended. Patients with non-valvular AF requiring interruption of warfarin or newer anticoagulants for procedures should balance the risks of stroke and bleeding when bridging against the duration of time that the patient will not be anticoagulated (NICE, 2014) .
The commonality of advancing age with AF requires that renal function should be monitored prior to initiating anticoagulants, re-evaluated when clinically indicated and further checked at least annually.
Switching between anticoagulants
It is important to consider how to switch safely between warfarin and DOACs (and vice versa) 
Conclusion
Future management of AF will incorporate new approaches and novel technologies to improve outcomes for patients with AF. With a large increase in the burden of AF expected in the coming decades, better diagnosis, integration of care, patient involvement and stratification of treatment selection by a multidisciplinary AF team could help to offset the impact of AF on healthcare services. The GP 5-year forward view supports management of chronic ailments such as AF in the community. It is important that GPs have a comprehensive and upto-date knowledge of the optimum management of AF and its complications. GPs should target minimising modifiable risk factors and optimising beneficial use of anticoagulants with shared and integrated care. Continued patient education also has the potential to alleviate disease burden in AF.
KEY POINTS
. AF is the most common cardiac arrhythmia; incidence and prevalence increase with age and 1-in-5 people over the age of 55 years are affected
. Prevention should target modifiable risk factors including obesity, thyroid disease, sleep apnoea, alcohol abuse and hypertension
. Treatment aims to relieve symptoms, prevent thromboembolism (including stroke) and maintain cardiac function
. CHA 2 DS 2 VASc should be used as screening tool to assess the need for anticoagulation with either DOACs or warfarin
. Optimising use of anticoagulants can alleviate disease burden; if poor anticoagulation control cannot be improved, evaluate and discuss the risks and benefits of alternative stroke prevention strategies with the patient . Refer as an emergency if fast heart rate compromises the patient (chest pain, hypotension or heart failure) or promptly if symptoms are uncontrolled or if difficulties with diagnosis or treatment
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Box 5. When to consider DOACs in preference to warfarin in non-valvular atrial fibrillation.
. Two INR tests are higher than 5.0 or one test higher than 8.0 within the previous 6 months
. Two INR values are less than 1.5 past in the previous 6 months
. The TTR scores are less than 65%
Also consider DOACs when:
. Where there is increased alcohol intake
. In conditions with more potential for drug interactions (e.g. needing repeat antibiotic courses etc.)
. When difficulties monitoring (e.g. travel difficulties etc.)
Source: NICE (2014).
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